# Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

> **NCT02481297** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Leukemia
- Chronic Lymphocytic Leukemia
- Lymphocytic Leukemia

## Interventions

- **DRUG:** Lirilumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02481297
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2019-08-15
- **Final completion:** 2019-08-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02481297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02481297, "Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02481297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*